GLP-1
Recent research & studies
- Incretin Therapies in Obesity-related HFpEF
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this…
- Semaglutide Therapy for Alcohol Reduction (STAR)
Background: Alcohol use disorder (AUD) is a problematic pattern of alcohol use accompanied by clinically significant medical consequences. Medications can help most people reduce their drinking, but the number is limited, and additional treatment options are needed. Objective: To test…
- Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)
Background: Artificial sweeteners like sucralose are found in many foods and drinks. Sucralose might affect hormones and cause health changes. Objective: To see if sucralose changes how medicines are absorbed and processed, how hormones are secreted, gut bacteria, and how…
- Avexitide for Treatment of Post-Bariatric Hypoglycemia
AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by…
- Efficacy of a Dietary Supplement for Telogen Effluvium Associated With GLP-1 Receptor Agonist Use: A Clinical, Subjective, and Trichogram Evaluation
A single-center, open-label clinical study to evaluate whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants will use the supplement for 120 days. Researchers will evaluate hair loss, hair density, and hair growth through…
- State-Level Variation in GLP-1 Receptor Agonist Use Among Medicaid Beneficiaries Without Diabetes by State Obesity Coverage Policy.
- Use of glucagon-like peptide-1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes.
Aims/introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) delay gastric emptying and may impair bowel preparation for colonoscopy. However, evidence in Asian populations is limited, and the impact of dosing frequency remains unclear. We examined the association between GLP-1RA use and inadequate…
- Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists have transformed the pharmacological management of type 2 diabetes (T2D) and obesity, yet substantial interindividual variability in treatment response remains a defining clinical challenge. Methods: Narrative review. PubMed was…
- Exploring the Therapeutic Potential of Bioactive Peptides in Modulating Tau Protein Interactions via the PI3K/Akt Pathway in Neurodegenerative Diseases.
Neurodegenerative Diseases (NDs) represent a growing global health challenge, characterized by progressive neuronal loss and cognitive decline. Central to these disorders are tauopathies, characterized by abnormal aggregation and hyperphosphorylation of tau proteins, leading to synaptic dysfunction and neuronal degeneration. Among…
- Venous Congestion in Metabolic Heart Disease: Potential Indirect Role of Dual Incretin Agonists.
Introduction: Venous congestion is responsible for symptoms, organ dysfunction, and negative outcomes in heart failure. In obesity-related Heart Failure (HF) with preserved ejection fraction (HFpEF), metabolic dysfunction, inflammation, endothelial damage, and sodium retention might exacerbate venous congestion. Method: This structured…
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
